摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Hexadecyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-beta-D-glucopyranoside

中文名称
——
中文别名
——
英文名称
Hexadecyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-beta-D-glucopyranoside
英文别名
(5-acetamido-3,4-diacetyloxy-6-hexadecoxyoxan-2-yl)methyl acetate
Hexadecyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-beta-D-glucopyranoside化学式
CAS
——
化学式
C30H53NO9
mdl
MFCD01118802
分子量
571.7
InChiKey
IQLBKMQSMVEUHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    40
  • 可旋转键数:
    24
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.87
  • 拓扑面积:
    127
  • 氢给体数:
    1
  • 氢受体数:
    9

文献信息

  • COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS
    申请人:THE JOHNS HOPKINS UNIVERSITY
    公开号:US20180280418A1
    公开(公告)日:2018-10-04
    The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS
    申请人:National Tuberous Sclerosis Association, Inc.
    公开号:US20190077874A1
    公开(公告)日:2019-03-14
    The treatment or prophylaxis of Tuberous Sclerosis Complex (“TSC”) and conditions associated with TSC is disclosed. Treatments involve the administration of one or more TLR4 inhibitors to patients with TSC. Such administration may also treat or forestall conditions associated with TSC, including epilepsy and lymphangioleiomyomatosis.
  • [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF TSC<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TSC
    申请人:NAT TUBEROUS SCLEROSIS ASSOCIATION INC
    公开号:WO2019055597A1
    公开(公告)日:2019-03-21
    The treatment or prophylaxis of Tuberous Sclerosis Complex ("TSC") and conditions associated with TSC is disclosed. Treatments involve the administration of one or more TLR4 inhibitors to patients with TSC. Such administration may also treat or forestall conditions associated with TSC, including epilepsy and lymphangioleiomyomatosis.
查看更多